IL6R and non-small cell lung carcinoma: However, while antibody-mediated approaches to neutralize IL6 (e.g., sirukumab and siltuximab) or block IL6R (e.g., tocilizumab) have demonstrated success in pre-clinical studies [158,168], phase I/II trials in patients with refractory/resistant NSCLC have yielded disappointing results (NCT00841191 [208], NCT00866970 [209,210]).